Prolastin C is used as a chronic augmentation and maintenance therapy in adults who have clinical evidence of emphysema due to severe hereditary Alpha-1 Proteinase Inhibitor (AAT) deficiency. This therapeutic measure addresses a condition characterized by periods of heightened symptoms and helps to manage the overall burden of symptoms that accompanies this genetic deficiency.

Supporting Symptom Stability

This long-term supportive measure is applied across clinical settings where additional symptomatic support is needed, helping to maintain a sense of stability during difficult episodes. It is relevant for easing groups of symptoms that may appear suddenly or fluctuate, such as symptoms related to physical discomfort and noticeable physiological strain. Prolastin C is commonly used for managing a condition characterized by periods of heightened symptoms.

Quick Fact: Support for Chronic Symptoms

Prolastin C assists with maintaining functional stability by helping to ease the overall symptom load that may interfere with routine activities. The therapy offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

1. NIH DailyMed Prescribing Information

Who Can and Cannot Use Prolastin C?

The eligibility for Prolastin C is governed by strict criteria established in regulatory prescribing information. The medication is officially indicated for use only in adults diagnosed with a severe hereditary deficiency of Alpha1-Proteinase Inhibitor (Alpha1-PI) who also exhibit clinical evidence of emphysema. The indication is limited strictly to patients meeting this dual genetic and clinical requirement.

Use of Prolastin C is formally contraindicated—meaning absolutely prohibited—for two specific groups. This includes IgA deficient patients with antibodies against IgA, due to the official risk of severe hypersensitivity reactions. It is also contraindicated for any patient with a documented history of anaphylaxis or other severe systemic reaction to any Alpha1-PI product.

Regarding age, the therapy is restricted to adults because the safety and efficacy have not been established in pediatric patients. Finally, the medication is not indicated as therapy for individuals in whom severe Alpha1-PI deficiency has not been definitively established, underscoring the necessity of a specific genetic diagnosis for eligibility.

Interactions with other medicines and products

The official regulatory profile for Prolastin C (Alpha-1-proteinase Inhibitor, Human) is characterized primarily by procedural constraints related to its physical administration. Due to the biological nature and formulation of this plasma-derived product, the prescribing information emphasizes a strict separation rule rather than systemic drug-drug interactions commonly seen with small-molecule medicines.

---

Administration-Related Restriction

A mandatory constraint documented by regulatory authorities, such as the U.S. Food and Drug Administration (FDA), is the requirement for physical separation during administration. Prolastin C must not be mixed with any other medicinal product, intravenous fluid, or diluting solution in the same infusion line. This restriction ensures the stability and function of the protein are maintained and prevents potential physical incompatibility. The drug must be infused separately as an intravenous solution.

---

Absence of Documented Systemic Interactions

Regulatory documents do not explicitly list or describe specific pharmacokinetic (e.g., CYP enzyme-mediated), pharmacodynamic, or systemic exposure-altering interactions with co-administered medications. Furthermore, the official prescribing information does not document any known interactions between Prolastin C and food, alcohol, or herbal products. The absence of specific warnings regarding these types of interactions is consistent across the authoritative regulatory summaries for this augmentation therapy product.

The mechanism of Prolastin C is a targeted, replacement strategy operating through the supply of the active protein Alpha-1-proteinase Inhibitor (A1-PI). This action modulates the protease-antiprotease equilibrium in the lung's extracellular space.

Neutralizing the Primary Destructive Enzyme

Prolastin C acts as an irreversible inhibitor of the enzyme Neutrophil Elastase (NE). A1-PI rapidly distributes to the lung tissue and forms a stable, covalent bond with NE, permanently neutralizing the enzyme. This direct molecular interaction functions to neutralize the enzyme, a key proteolytic agent present in the lungs, thereby engaging the protease-antiprotease balance.

Protecting Structural Integrity of Lung Tissue

The molecular consequence of NE neutralization is the protection of the enzyme's natural substrates, primarily elastin and collagen. By limiting proteolytic activity, the mechanism helps stabilize the connective tissue framework of the alveolar walls against enzymatic degradation. This action contributes to the maintenance of the mechanical stability of the lung parenchyma.

Administration Guidelines for Prolastin-C

The following information defines the procedure for using Prolastin-C in adults.

Administration Detail	Requirement
Route of Administration	Intravenous (IV) use only.
Dosing Regimen	The recommended dose is 60 mg per kg of body weight, administered once weekly.
Infusion Rate	Administer intravenously at a rate of 0.08 mL/kg/min or greater. The infusion typically takes approximately 15 minutes at this recommended rate.

Preparation and Procedural Steps

The Prolastin-C liquid solution requires specific handling steps before administration:

1. Warm to Room Temperature: Unopened vials must be allowed to warm to room temperature prior to use.
2. Inspection and Pooling: The solution should be visually inspected; it should be clear and may be colorless, pale yellow, or pale green. The dose, which may require pooling the content of several vials, must be transferred into a sterile intravenous container using aseptic technique.
3. Time Constraint: The pooled solution must be administered within three hours of pooling.
4. Special Conditions: The product must be infused separately and should not be mixed with other agents or diluting solutions. The solution must be filtered during administration using an intravenous administration set equipped with a suitable 5 to 15 micron infusion filter.

Research Evidence / Overview of Studies for Prolastin C

---

Evidence for Chronic Augmentation Therapy in Emphysema due to AAT Deficiency

Research into Prolastin C was studied for its role as a long-term augmentation therapy for adults with severe Alpha-1 Antitrypsin (AAT) deficiency who have developed emphysema. The therapy was studied in the context of emphysema due to AAT deficiency. The body of evidence for this use includes randomized, placebo-controlled clinical trials (RCTs), which are a high standard of research, alongside long-running observational studies and patient registry analyses.

These studies were conducted on adults with established lung disease resulting from the deficiency. Research examined the patterns observed during the study period over time in a setting of a chronic, inherited condition. Findings describe patterns observed in these studies, specifically by examining certain markers over defined time intervals.

---

Outcomes Studied: Biochemical Markers and Physical Disease Progression

One major area of research explored the therapy by monitoring biochemical markers. Studies consistently reported measurements showing that the medication, when given intravenously, raises the Alpha-1 Antitrypsin protein level in both the blood and the fluid lining the lungs. Raising these levels above a certain threshold was a key biochemical marker monitored in these research scenarios.

---

Outcomes Studied: Lung Function and Clinical Symptom Monitoring

Research has also explored traditional measures of lung health and patient experience. Studies monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes. This included monitoring the rate of decline in lung function tests (such as FEV₁ measurements) and tracking the frequency of sudden worsening of respiratory symptoms (pulmonary exacerbations).

However, findings related to the rate of decline in lung function and the frequency of these acute episodes were mixed and varied across the different clinical trials. Studies monitored outcomes related to physical discomfort and outcomes describing episodic or acute changes; however, findings were mixed across different study settings.

---

Extended and Long-Term Follow-up Research

Because emphysema is a condition that progresses slowly over many years, researchers have conducted extended studies to look beyond the duration of the initial clinical trials, which typically had follow-up durations limited to 2 to 4 years. Observational studies and patient registries have monitored individuals within the study population for periods of up to seven years or more.

Key Studies & References

1. PROLASTIN-C LIQUID (Alpha1-Proteinase Inhibitor [Human]) Solution for Intravenous Injection Full Prescribing Information
2. Multi-center, Randomized Trial With I.V. Prolastin® to Evaluate Frequency of Exacerbations and Progression of Emphysema by Means of Multi-slice CT Scans in Patients With Congenital Alpha-1-antitrypsin Deficiency (EXACTLE)

Common questions about Prolastin C (FAQ)

---

Q: Do people take Prolastin C for long-term health?

According to the official product information, Prolastin C is classified as a chronic augmentation and maintenance therapy.

It is used over the long term for adults diagnosed with severe hereditary Alpha-1 proteinase inhibitor (PI) deficiency who also have emphysema. The goal is to provide sustained levels of the Alpha-1 PI protein in the body.

---

Q: Does Prolastin C actually cure Alpha-1 deficiency?

Prolastin C is a replacement therapy intended to supplement the low protein levels caused by the inherited genetic deficiency.

Official limitations of use state that the effect of this augmentation therapy on the actual progression of emphysema has not been conclusively demonstrated in large-scale clinical trials. Therefore, its role is consistent with a chronic, maintenance therapy, rather than a curative treatment for the underlying genetic condition.

---

Q: Can Prolastin C improve my lung function?

Official research investigated whether the therapy helps slow the rate of decline in lung function over time, rather than establishing claims of functional improvement.

Study findings related to the rate of decline in lung function measurements, such as FEV₁, have been described in published literature as mixed and varied across different trials.

---

Q: Can someone who smokes still be eligible for Prolastin C?

Official regulatory documents identify smoking as a significant risk factor for the development and progression of emphysema in patients with this deficiency.

However, current smoking status is not listed as a formal contraindication (a prohibited condition) in the official labeling for the medication.

---

Q: Is Prolastin C recommended for people with liver disease related to Alpha-1?

Prolastin C is officially indicated only for the treatment of emphysema associated with severe hereditary Alpha-1 PI deficiency.

It is not indicated as a therapy for the specific liver disease manifestations that can also be related to the Alpha-1 protein deficiency.

---

Q: Does Prolastin C contain any components that might cause an allergic reaction?

Yes, the product is derived from human plasma and contains components that can lead to allergic reactions.

It is formally contraindicated (prohibited) for use in patients who are IgA deficient and have developed antibodies against IgA, due to a severe risk of hypersensitivity reactions, including potentially life-threatening anaphylaxis.

---

Q: Does Prolastin C have any known drug interactions with blood thinners?

The official prescribing information does not describe or list any specific systemic interactions with co-administered medications like blood thinners.

A key constraint is procedural: Prolastin C must never be mixed with any other medicinal product, intravenous fluid, or diluting solution in the same infusion line.

---

Q: Where does the plasma used to make Prolastin C come from?

The active ingredient, Alpha-1-proteinase Inhibitor, Human, is classified as a plasma-derived product.

The protein is purified from large pools of human plasma that has been donated and screened through established safety protocols.

---

Q: Is it safe to drive after receiving a Prolastin C infusion?

Common adverse reactions observed during clinical studies include dizziness and fatigue.

Although the official label does not provide specific advice about driving, patients should be aware of these known side effects and how they might affect the ability to drive or operate machinery.

---

Q: What kind of studies were performed to get Prolastin C approved?

The research evidence supporting the therapy includes randomized, placebo-controlled clinical trials, which are considered a high standard of research.

This body of evidence is complemented by long-running observational studies and analyses from patient registries.

---

Q: Can Prolastin C affect fertility in men or women?

According to the official regulatory documents, there is currently no available clinical data on the use of this product to assess its potential for affecting reproductive capacity or causing fetal harm.

Animal studies specifically designed to assess effects on reproductive capacity have not been conducted.

---

Q: Does Prolastin C make it harder to fight off colds or the flu?

Clinical trials reported that Upper Respiratory Tract Infection and Urinary Tract Infection are among the most common adverse reactions, occurring in more than 5% of subjects.

---

Q: Is Prolastin C linked to any heart problems?

When reviewing the official safety profile for the medication, the list of most common or serious adverse reactions documented in clinical trials does not include specific cardiovascular events or heart problems.

---

Q: Are there any dietary restrictions required when using Prolastin C?

The official prescribing information confirms that there are no documented known systemic interactions between Prolastin C and food, alcohol, or herbal products.

This information covers systemic interactions; however, the product must be infused separately and not mixed with any other solutions.

---

Q: Is it possible to become resistant to the effects of Prolastin C over time?

Official labeling discusses the risk of the body having an allergic response (hypersensitivity reaction) to the protein.

The clinical studies included assessments of immunogenicity, which is the potential for the body to develop antibodies against the product.

---

Q: What happens if I miss a scheduled infusion of Prolastin C?

The official guidance for a missed infusion is that a patient is directed to contact a healthcare provider immediately to reschedule the infusion and determine the appropriate next steps for continuing the treatment plan.

---

Q: Are there age limits for who can use Prolastin C?

The therapy is officially restricted to adults for use, as the safety and efficacy have not been formally established in pediatric patients.

To note, the prescribing information states the safety and efficacy have also not been formally established in geriatric patients, although small numbers of older adults were included in the clinical trials.

---

Q: Is it normal to feel tired after receiving a Prolastin C infusion?

Fatigue is listed in the official safety profile as one of the most common adverse reactions, reported by more than 5% of subjects in clinical trials.

It is therefore described in official documents as a possible, documented effect that patients may experience.

---

Q: Can alcohol consumption affect the safety of Prolastin C treatment?

The official prescribing information for Prolastin C does not document any known systemic interactions between the product and alcohol.

This is consistent with its biological nature as a plasma-derived protein replacement therapy.

---

Q: Is Prolastin C safe to use during pregnancy?

There is currently no clinical data available on the use of this drug in pregnant women to fully assess the risks of fetal harm or effects on the course of pregnancy.

Official documentation states the product should be used during pregnancy only if clearly needed.

---

Q: What kind of monitoring is typically done while a patient is on Prolastin C?

During the infusion, patients should be continuously monitored and vital signs observed carefully.

Additionally, official warnings note that clinical staff are required to monitor the patient for signs of hypersensitivity or severe systemic reactions due to the product’s nature.

---

Q: Do studies suggest Prolastin C slows down the progression of lung damage?

The official regulatory limitations state that the effect of augmentation therapy on the overall progression of emphysema has not been conclusively demonstrated in randomized, controlled clinical trials.

Studies have consistently shown that the treatment successfully raises the Alpha-1 Antitrypsin protein levels in the blood and lung fluid.

---

Q: Is Prolastin C treatment lifelong?

Prolastin C is officially indicated as a chronic augmentation and maintenance therapy for the condition.

The official label notes that clinical data demonstrating the full long-term effects of this chronic augmentation or maintenance therapy are not available beyond the initial study periods.

Official Storage and Disposal Instructions

Prolastin-C Liquid requires strict adherence to regulatory storage conditions to maintain the stability of the Alpha-1-proteinase Inhibitor protein. The product must be stored under refrigeration between 2 C and 8 C (36 F and 46 F) until the expiration date and must not be frozen.

It should be stored in its original container to protect it from light and kept out of the reach of children. The product may be stored at controlled room temperature (up to 25 C) for a single period of up to one month, but it cannot be returned to the refrigerator after this time.

Any unused portion of the solution must be discarded immediately after administration. All used administration equipment, including needles and vials, must be disposed of in a sharps container following appropriate biohazard procedures, and should not be placed in household waste.